3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline

We are 3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline CAS:154057-56-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline
CAS.NO:154057-56-4
Synonyms:3-(bromomethyl)-2-cyclopropyl-4-(4'-flourophenyl)quinoline
2-cyclopropan-3-bromomethyl4-(4-fluorophenyl)-3-quinoline
Molecular Formula:C19H15BrFN
Molecular Weight:356.23200
 
Physical and Chemical Properties:
Density:1.461
Boiling point:467.62ºC
Flash point:236.608ºC
 
Specification:
Appearance:White to off-white crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediates of Rosuvastatin Calcium

3-(Bromomethyl)-2-cyclopropyl-4-(4-fluorophenyl)quinoline


Related News: The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon.N-Methyl acetoacetamide Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. Clorhidrato de 2-aminoacetofenona CAS:5468-37-1 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.63-37-6 We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
3,5-Bis(trifluoromethyl)bromobenzene View Details
1-methoxy-3-nitro-5-(trifluoromethyl)benzene View Details
trans-4-Methylcyclohexyl amine View Details
N-phenyl-[1,1′,4′,1”-terphenyl]-4-amine manufacturer (4S)-4-propan-2-yl-1,3-oxazolidine-2,5-dione manufacturer Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate manufacturer 2-(o-bromophenyl)-4,6-diphenyl-1,3,5-triazine manufacturer L-Norvaline manufacturer